Spironolactone for Heart Failure with Preserved Ejection Fraction
2014 · New England Journal of Medicine · 2,626 citations
https://doi.org/10.1056/nejmoa1313731
B
Brian Claggett
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
1.0K
Papers
45.1K
Citations
101
h-index
483
i10-index
Brian Claggett is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Heart Failure Treatment and Management & Cardiovascular Function and Risk Factors & Diabetes Treatment and Management. The author has an h-index of 101, co-authored 878 publications.
ORCID: 0000-0002-4215-9218Papers by this author
worksDapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
2022 · New England Journal of Medicine · 2,390 citations
https://doi.org/10.1056/nejmoa2206286
Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction
2019 · New England Journal of Medicine · 2,229 citations
https://doi.org/10.1056/nejmoa1908655
SGLT2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials
2022 · The Lancet · 825 citations
https://doi.org/10.1016/s0140-6736(22)01429-5
Dietary carbohydrate intake and mortality: a prospective cohort study and meta-analysis
2018 · The Lancet Public Health · 747 citations
https://doi.org/10.1016/s2468-2667(18)30135-x
Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials
2020 · The Lancet · 627 citations
https://doi.org/10.1016/s0140-6736(20)30748-0
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat